A Phase 4 interventional study of Trospium Chloride, Extended Release (XR) and placebo in Obesity, Overactive Bladder and Incontinence, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-21.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 127 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
Drug: Trospium Chloride, Extended Release (XR) · Other: placebo
Placebo capsule taken orally once daily for 14 weeks.
Other: placebo
Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
Also known as: Sanctura XR™ 60 mg
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Percent Change From Baseline in Urinary Urgency Incontinence (UUI)
Patients recorded information about UUI (accidental leakage, urgency associated with void and urgency severity) in a 3-day diary at Baseline (Week 2) and Week 14. The daily average episodes of UUI was the sum of all UUI episodes over valid diary days during the 3-day diary period divided by the valid number of diary days with at least one valid bladder entry. The percent change from baseline was calculated as (Mean UUI at Week 14- Mean UUI at Week 2)/ Mean UUI at Week 2 X 100. A negative number percent change from baseline indicated an improvement.
Time frame: Baseline (Week 2), Week 14
Percent Change From Baseline in Urgency Severity Associated With Toilet Voids
Due to lack of evaluable data, analysis for this outcome measure was not performed.
Time frame: Baseline (Week 2), Week 14
Percent Change From Baseline in Voided Volume
Due to lack of evaluable data, analysis for this outcome measure was not performed.
Time frame: Baseline (Week 2), Week 14
Percent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score
Due to lack of evaluable data, analysis for this outcome measure was not performed.
Time frame: Baseline (Week 2), Week 14
Percent Change From Baseline in Percentage of Patients Continent
Due to lack of evaluable data, analysis for this outcome measure was not performed.
Time frame: Baseline (Week 2), Week 14
| Milestone | Trospium Chloride XR 60 mg | Placebo |
|---|---|---|
| Started | 64 | 63 |
| Completed | 59 | 59 |
| Not completed | 5 | 4 |
Patients recorded information about UUI (accidental leakage, urgency associated with void and urgency severity) in a 3-day diary at Baseline (Week 2) and Week 14. The daily average episodes of UUI was the sum of all UUI episodes over valid diary days during the 3-day diary period divided by the valid number of diary days with at least one valid bladder entry. The percent change from baseline was calculated as (Mean UUI at Week 14- Mean UUI at Week 2)/ Mean UUI at Week 2 X 100. A negative number percent change from baseline indicated an improvement.
| Percent change | Trospium Chloride XR 60 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Urinary Urgency Incontinence (UUI) | -23.7 ± 36.16 | 57.8 ± 275.3 |
Due to lack of evaluable data, analysis for this outcome measure was not performed.
No measurements were reported for this outcome.
Due to lack of evaluable data, analysis for this outcome measure was not performed.
No measurements were reported for this outcome.
Due to lack of evaluable data, analysis for this outcome measure was not performed.
No measurements were reported for this outcome.
Due to lack of evaluable data, analysis for this outcome measure was not performed.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trospium Chloride XR 60 mg | — | 0/64 (0%) | 6/64 (9.4%) |
| Placebo | — | 1/63 (1.6%) | 3/63 (4.8%) |
| Event | Trospium Chloride XR 60 mg | Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/64 | 1/63 |
| Event | Trospium Chloride XR 60 mg | Placebo |
|---|---|---|
| Dry mouthGeneral disorders | 6/64 | 3/63 |
| Age, Customized(Participants) | Trospium Chloride XR 60 mg | Placebo | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18 to 75 years | 64 | 63 | 127 |
| >75 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Trospium Chloride XR 60 mg | Placebo | Total |
|---|---|---|---|
| Female | 64 | 63 | 127 |
| Male | 0 | 0 | 0 |
The record gives a start of Jul 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trospium chloride